跳转至内容
Merck
CN

SML2482

替格瑞洛

≥98% (HPLC), adensoine purinoceptor P2Y12 receptor antagonist, powder

别名:

替格瑞洛, (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-二氟苯基)环丙基]氨基}-5­(丙硫基)-3H-[1,2,3]-三唑并[4,5-d]吡啶基-3-yl]-5-(2-羟基乙氧基)环戊烷-1,2-二醇, (1 S ,2 S ,3 R ,5 S )-3-[7-{[(1 R ,2 S )-2-（3,4-二氟苯基）环丙基] 氨基 }-5-（丙基砜基）-3 H - [1,2,3] 三唑 [4,5- d 嘧啶-3-基]-5-（2-羟乙氧基）-1,2-环戊二醇

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C23H28F2N6O4S
化学文摘社编号:
274693-27-5
分子量:
522.57
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
MFCD09954148
Assay:
≥98% (HPLC)
Form:
powder

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

替格瑞洛, ≥98% (HPLC)

InChI key

OEKWJQXRCDYSHL-FNOIDJSQSA-N

SMILES string

FC1=C(F)C=C([C@]2([H])C[C@@]2([H])NC3=NC(SCCC)=NC4=C3N=NN4[C@]5([H])C[C@H](OCCO)[C@@H](O)[C@H]5O)C=C1

InChI

1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -55 to -65°, c = 0.2 in methanol

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Gene Information

human ... P2RY12(64805)

正在寻找类似产品? 访问 产品对比指南

相关类别

Biochem/physiol Actions

替格瑞洛是一种抗血栓形成抗血小板药物，直接和可逆地竞争性抑制腺嘌呤受体P2Y12受体发挥作用。可用于治疗急性冠状动脉综合征患者。也可改善内皮功能。替格瑞洛可抑制人红细胞摄取腺苷，促进人红细胞释放腺苷三磷酸(ATP)。

General description

替格瑞洛(AZD6140)是一种环戊基三唑嘧啶。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000388592
0000388594
0000329672
0000329672
0000388594

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Athanasios Moulias et al.
Journal of cardiovascular pharmacology and therapeutics, 24(1), 11-17 (2018-07-12)
Ticagrelor is a P2Y12 receptor antagonist with proven clinical benefit in patients with acute coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been implicated in the clinical profile of ticagrelor, including a potentially beneficial impact on endothelial
Michał J Kubisa et al.
Therapeutics and clinical risk management, 14, 129-140 (2018-02-06)
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor
José C Nicolau et al.
Expert opinion on pharmacotherapy, 19(9), 1013-1019 (2018-06-13)
Cardiovascular disease (CVD) is the main cause of death in the world. Coronary artery disease (CAD) is the most common form of CVD presentation, but the prevalence of peripheral artery disease (PAD) is increasing. Patients with polyvascular disease comprise a
Riyaad Aungraheeta et al.
Blood, 128(23), 2717-2728 (2016-10-04)
Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis. Here, we sought to further characterize its molecular mechanism of action. Initial studies showed that ticagrelor promoted

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持